Melatonin prolonged release: In the treatment of insomnia in patients aged ≥55 years

Drugs and Aging

Volumn 29, Issue 11, 2012, Pages 911-923

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALCOHOL; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450; ESTROGEN; ESZOPICLONE; FLUVOXAMINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; METHOXSALEN; OPIATE AGONIST; OPIATE ANTAGONIST; PLACEBO; PROSTAGLANDIN INHIBITOR; QUINOLONE DERIVATIVE; RIFAMPICIN; TEMAZEPAM; TRYPTOPHAN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ACTIMETRY; ARTHRALGIA; ARTICLE; BACKACHE; BEDTIME DOSAGE; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; FIRST PASS EFFECT; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; JET LAG; MEDLINE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; RHINOPHARYNGITIS; SCORING SYSTEM; SINGLE DRUG DOSE; SLEEP WAKING CYCLE; SUBSTITUTION THERAPY;

CENTRAL NERVOUS SYSTEM DEPRESSANTS; DELAYED-ACTION PREPARATIONS; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; MIDDLE AGED; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84874601219     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0018-z     Document Type: Article

References (44)

1. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577-601.
2. Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57(5):761-89.
3. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
4. Zisapel N. Drugs for insomnia. Expert Opin Emerg Drugs. 2012;17(3):299-317.
5. Léger D, Morin CM, Uchiyama M, et al. Chronic insomnia, quality-of-life, and utility scores: comparison with good sleepers in a cross-sectional international survey. Sleep Med. 2012;13(1):43-51.
6. Roth T, Franklin M, Bramley TJ. The state of insomnia and emerging trends. Am J Managed Care. 2007;13(5 Suppl):S117-20.
7. Ohayon MM, Carskadon MA, Guilleminault C, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27(7):238-9.
8. Conn DK, Madan R. Use of sleep-promoting medications in nursing home residents: risks versus benefits. Drugs Aging. 2006;23(4):271-87. (Pubitemid 43830659)
9. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169. (Pubitemid 41689427)
10. Huang AR, Mallet L, Rochefort CM, et al. Medication-related falls in the elderly: causative factors and preventative strategies. Drugs Aging. 2012;29(5):359-76.
11. McIntyre IM, Norman TR, Burrows GD, et al. Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans. Chronobiol Int. 1993;10(3):205-13. (Pubitemid 23185016)
12. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):61-82. (Pubitemid 36363607)
13. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf. 2009;32(9):735-48.
14. Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs. 2007;21(5):389-405. (Pubitemid 46698502)
15. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119(6):821-46.
16. Cardinali DP, Srinivasan V, Brzezinski A, et al. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365-75.
17. Circadin 2 mg prolonged-release tablets: summary of product characteristics. London: European Medicines Agency; 2012.
18. Hardeland R, Poeggeler B, Srinivasan V, et al. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. (Pubitemid 351220148)
19. Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs. 2007;21(12):995-1018. (Pubitemid 350136783)
20. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat. 2009;5(1):341-54.
21. Haimov I. Melatonin rhythm abnormalities and sleep disorders in the elderly. CNS Spectr. 2001;6(6):502-6. (Pubitemid 32622746)
22. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116(2):91-5. (Pubitemid 38056661)
23. Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995;346(8974):541-4.
24. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr. 1997;24(2):223-31. (Pubitemid 27072996)
25. Lissoni P, Rovelli F, Pittalis S, et al. Therapy with melatonin does not suppress its endogenous production in healthy volunteers [in Italian]. Recenti Prog Med. 1999;90(2):84-5. (Pubitemid 29140707)
26. Lemoine P, Garfinkel D, Laudon M, et al. Prolonged-release melatonin for insomnia: an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011;7:301-11.
27. Garfinkel D, Zorin M, Wainstein J, et al. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307-13.
28. Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24(5):239-49.
29. Otmani S, Demazieres A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol Clin Exp. 2008;23(8):693-705.
30. Otmani S, Metzger D, Guichard N, et al. Effects of prolonged-release melatonin and zolpidem on postural stability in older adults. Hum Psychopharmacol Clin Exp. 2012;27(3):270-6.
31. Paul MA, Gray G, Kenny G, et al. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med. 2003;74(12):1263-70. (Pubitemid 37523132)
32. European public assessment report for Circadin: scientific discussion. London: European Medicines Agency; 2007.
33. Aperis G, Prakash P, Paliouras C, et al. The role of melatonin in patients with chronic kidney disease undergoing haemodialysis. J Ren Care. 2012;38(2):86-92.
34. Lemoine P, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16(4):372-80. (Pubitemid 350151283)
35. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10):2597-605. (Pubitemid 350033462)
36. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87-98.
37. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations: a review. Psychopharmacology (Berl). 1980;71(2):173-9. (Pubitemid 11254055)
38. Backhaus J, Junghanns K, Broocks A, et al. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002;53(3):737-40.
39. Bech P, Olsen LR, Kjoller M, et al. Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. Int J Methods Psychiatr Res. 2003;12(2):85-91. (Pubitemid 36850039)
40. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51.
41. Lemoine P, Wade AG, Katz A, et al. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integr Blood Press Control. 2012;5:9-17.
42. Garfinkel D, Zisapel N, Wainstein J, et al. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159(20):2456-60. (Pubitemid 29526774)
43. Kunz D, Bineau S, Maman K, et al. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012;13(1):9-16.
44. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 63. London: BMJ Publishing Group Ltd and RPS Publishing; 2012.